Laigo Bio

About Laigo Bio

Laigo Bio is a biotechnology company pioneering protein degradation for targeted therapies. They focus on eradicating disease-causing targets, including those previously considered undruggable, using their proprietary SureTAC platform to develop innovative treatments and forge a path toward a healthier tomorrow.

Products & Services

SureTACs (Surface Removal Targeting Chimeras):A novel technology using bispecific antibodies to facilitate precise removal of cell surface proteins via ubiquitin-mediated degradation. It targets undruggable proteins, offers deeper pathway inhibition, and provides tissue-specific action, initially focusing on oncology with expansion into immunology and neuroinflammation.

Specialties

Protein Degradation Targeted Therapies Bispecific Antibodies Oncology Immunology Neuroinflammation E3 Ligase Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 12650000 MR: - FA: €11.5 million FAN: 12650000	D: 2025-12-04 FD: 2025-12-04	8 investors

Seed Latest

2025-12-04

$12.7M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Matthew Baker

CEO

N

Neill Moray Mackenzie

Co-founder & Chair

M

Madelon Maurice

Scientific Founder

Q

Qi Liang

CDO

M

Maureen Spit

VP, Research

A

Aisha Krishna

Director of Operations

View 3 more team members with Pro

Unlock Full Team Directory

Recent News

Laigo Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised